3.4 Toxicities
Common late adverse effects were mainly skin/mucosal
toxicities. There were 2 cases of late severe adverse effects
(6.5%), including one case of grade 4 mandibular osteonecrosis and one
case of grade 3 skin/mucosal toxicity. The patient suffered from
mandibular osteonecrosis had received two courses of EBRT before last
recurrence, of which the total dose accumulated to 138Gy. Another
patient suffered from grade 3 skin/mucosal toxicity had received one
course of EBRT for a total dose of 70Gy. Besides, eleven patients
(41.9%) suffered from late grade 1-2 adverse effects, including ten
cases (32.2%) of skin/mucosal toxicities and one case (3.2%) of pain.